EGFR and non-small cell lung carcinoma: In NSCLC models, Hata et al. proposed that late-emerging EGFR T790M-acquired resistance results from the evolution of drug-tolerant cells, and showed that these cells displayed a reduced apoptotic response during EGFR-TKI treatment.